THE RELIABILITY AND UTILITY OF BLOOD EOSINOPHILS AS A MARKER OF DISEASE BURDEN, HEALTHCARE RESOURCE UTILISATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (BLOOD EOSINOPHIL COUNT AND COPD)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/28222
• EU PAS number:
  EUPAS4921
• Study ID:
  28222
• Official title and acronym:
  THE RELIABILITY AND UTILITY OF BLOOD EOSINOPHILS AS A MARKER OF DISEASE BURDEN, HEALTHCARE RESOURCE UTILISATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (BLOOD EOSINOPHIL COUNT AND COPD)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  The proposed study will use the United Kingdom's Optimum Patient Care Research Database (OPCRD) to explore the relationship between blood eosinophil count and future exacerbation risk in COPD. Additional analysis will also aim to validate blood eosinophil count as a reliable, stable and responsive measure to assess its utility as a marker of disease risk. Exploratory investigations will also seek to characterise features of COPD patients with eosinophila in terms of their COPD stage, comorbid conditions and other clinical characteristics (respiratory symptoms, past history of exacerbations, risk factors).
• Study status:
  Finalised

Research institution and networks

Institutions

Research in Real Life

Networks

Respiratory Effectiveness Group (REG)

Belgium

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Spain

Sweden

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 01/11/2013

Actual: 08/11/2013

Study start date

Planned: 04/11/2013

Actual: 18/11/2013

Date of final study report

Planned: 30/04/2014

Actual: 30/07/2014

Sources of funding

Other

More details on funding

Respiratory Effectiveness Group, Research in Real Life

Study protocol

Initial protocol

REG_COPD Eosinophil Study Protocol_8Nove_ADEPT APPROVED

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable